Vyant Bio, Inc.
VYNT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $7 |
| % Growth | -42% | 32.4% | -88.1% | – |
| Cost of Goods Sold | $1 | $2 | $1 | $4 |
| Gross Profit | -$0 | -$1 | -$0 | $4 |
| % Margin | -51.4% | -60.9% | -27% | 49.3% |
| R&D Expenses | $7 | $4 | $3 | $0 |
| G&A Expenses | $0 | $0 | $0 | $5 |
| SG&A Expenses | $9 | $8 | $3 | $6 |
| Sales & Mktg Exp. | $9 | $8 | $3 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $13 | $6 | $6 |
| Operating Income | -$16 | -$16 | -$8 | -$3 |
| % Margin | -2,389.2% | -1,368.1% | -879.2% | -37.1% |
| Other Income/Exp. Net | $0 | -$3 | -$1 | -$5 |
| Pre-Tax Income | -$16 | -$19 | -$9 | -$7 |
| Tax Expense | $7 | $28 | $1 | -$1 |
| Net Income | -$23 | -$46 | -$9 | -$7 |
| % Margin | -3,406.9% | -4,015.2% | -1,060.7% | -91.8% |
| EPS | -3.87 | -10.19 | -18.5 | -17.4 |
| % Growth | 62% | 44.9% | -6.3% | – |
| EPS Diluted | -3.87 | -10.19 | -18.5 | -17.4 |
| Weighted Avg Shares Out | 6 | 5 | 0 | 0 |
| Weighted Avg Shares Out Dil | 6 | 5 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $1 | $8 | $3 | $1 |
| EBITDA | -$15 | -$16 | -$5 | -$2 |
| % Margin | -2,232.9% | -1,368.1% | -583.9% | -30.3% |